Fate Therapeutics
Primary Menu
Skip to content
About Us
Our Mission
Our Cells of Interest
Management
Board of Directors
Pipeline
Overview
Immuno-Oncology Candidates
FT500
FT516
FT596
FT538
FT576
FT819
Immuno-Regulation Candidates
ProTmune
™
FT301
Early/Expanded Access Policy
Science
Ex Vivo
Cell Modulation
iPSC Platform
Manufacturing
Publications
Collaborations
Join Our Team
Vision, Mission, Values
Working at Fate
Career Opportunities
Investors
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
One Cell. Many Fates.
for
immuno-oncology
[CD34
+
]
for
immuno-regulation
[T-Cell, NK Cell]
About Us
Our Mission
Our Cells of Interest
Management
Board of Directors
Pipeline
Overview
Immuno-Oncology Candidates
FT500
FT516
FT596
FT538
FT576
FT819
Immuno-Regulation Candidates
ProTmune
™
FT301
Early/Expanded Access Policy
Science
Ex Vivo
Cell Modulation
iPSC Platform
Manufacturing
Publications
Collaborations
Join Our Team
Vision, Mission, Values
Working at Fate
Career Opportunities
Investors
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact